New drug switch strategy aims to outsmart tough breast cancer
NCT ID NCT07151586
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests if switching between two different targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) can help people with a hard-to-treat, advanced breast cancer called HER2-low triple-negative breast cancer live longer. About 260 adults with metastatic or locally advanced cancer will be randomly assigned to get either the alternating drug combo or just one drug alone. The main goal is to see if the alternating approach improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
Villejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
institut Paoli calmette
Marseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.